SCHEMBL2843024

SCHEMBL2843024

Cc1c(C#N)sc2nc(-c3ccc(Cl)cc3)[nH]c(=O)c12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TMIGD3 P0DMS9 1/20 0.46
ADORA1 P30542 1/20 0.46
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 4/20 0.46
HPGD P15428 4/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TNKS O95271 2/20 0.43
TNKS2 Q9H2K2 2/20 0.43
PARP2 Q9UGN5 2/20 0.43
MAPK1 P28482 2/20 0.43
HSD17B10 Q99714 1/20 0.43
LMNA P02545 2/20 0.42
GUSB P08236 1/20 0.41
KMT2A Q03164 1/20 0.40
CDKN1A P38936 3/20 0.40
IDO1 P14902 1/20 0.40
BRD4 O60885 3/20 0.40
RNASEL Q05823 1/20 0.40
MAPT P10636 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2843704 0.90 KDM4E (0.50) TMIGD3ADORA1ALDH1A1KDM4EHPGD
SCHEMBL2837248 0.88 ALDH1A1 (0.61) TMIGD3ADORA1ALDH1A1KDM4EHPGD
SCHEMBL2838028 0.86 ALDH1A1 (0.57) TMIGD3ADORA1ALDH1A1KDM4EHPGD
SCHEMBL2839683 0.86 CDKN1A (0.56) TMIGD3ADORA1ALDH1A1KDM4EHPGD
SCHEMBL13475914 0.86 TMIGD3 (0.45) TMIGD3ADORA1ALDH1A1KDM4EHPGD
SCHEMBL2837355 0.85 BRD4 (0.55) TMIGD3ADORA1ALDH1A1KDM4EHPGD
SCHEMBL2837954 0.84 TNKS (0.47) TMIGD3ADORA1ALDH1A1KDM4EHPGD
SCHEMBL13475911 0.82 TNKS (0.49) TMIGD3ADORA1ALDH1A1KDM4EHPGD
SCHEMBL2833833 0.81 FGFR1 (0.52) TMIGD3ADORA1ALDH1A1KDM4EHPGD
SCHEMBL2835633 0.79 PARP1 (0.48) TMIGD3ADORA1ALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662814-B2 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases LABORATORIOS ALMIRALL, S.A. (ES) 2010-02-16 US disclosed
US-7662814-B2 4-(4-Ethylpiperazin-1-yl)-5-methyl-2-phenylthieno[2,3-d]pyrimidine-6-carbonitrile; asthma, atopic dermatitis, chronic obstructive pulmonary disease, Crohn's disease, type I and type II diabetes, lymphoid leukemia and other forms of cancer, multiple sclerosis and autoimmune diseases LABORATORIOS ALMIRALL, S.A. (ES) 2010-02-16 US disclosed
EP-1590352-B1 4-AMINOTHIENO [2,3-d] PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS ALMIRALL LAB (ES) 2007-06-27 EP disclosed
US-20060229306-A1 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors LABORATORIOS ALMIRALL, S.A. (ES) 2006-10-12 US disclosed
WO-2004065391-A1 4-AMINOTHIENO[2,3-d]PYRIMIDINE-6-CARBONITRILE DERIVATIVES AS PDE7 INHIBITORS ALMIRALL PRODESFARMA S.A. (ES) 2004-08-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229306-A1 4-Aminothieno[2,3-d]pyrimidine-6-carbonitrile derivatives as pde7 inhibitors PDE7B, PDE7A, PDE3A TMIGD3 3801/4885ADORA1 270/4885ALDH1A1 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.